Biden too focused on vaccines to deal with therapeutics?

 Epoch Times:

...

(Dr. Marc) Siegel said that the Biden administration has not been able to deliver any therapeutics for early treatment of people with mild or moderate COVID-19 because of the administration’s “obsessive focus on the vaccines to the exclusion of all else.”

“When it comes to therapeutics, the Biden team’s results are even more anemic,” Siegel wrote in an op-ed in USA Today. “Paxlovid, Pfizer’s new protease inhibitor wonder drug, has been approved but is scarce.”

“Ditto monoclonal antibodies, the synthetic neutralizing antibodies that have been so helpful in patients at high risk of complications or hospitalizations. Omicron is most susceptible to sotrovimab, made by GlaxoSmithKline, but in most states, it is almost impossible to find,” he added.

The Epoch Times has reached out to the Biden administration for comment.

The U.S. Department of Health and Human Services (HHS) has delivered over 197,000 courses of the monoclonal antibody treatments to state and territorial health departments, and to federal entities for the week of Jan. 3. This comes after the agency briefly paused distribution of the treatments on Dec. 23.
...

The lack of messaging around monoclonal antibody treatments from federal authorities resulted in people being unaware of the short timeframe to receive these effective therapies (within 10 days of experiencing the first symptoms) and some hospitals refusing to use them. This led to low demand for the monoclonal antibodies at a time when it should have been utilized to help alleviate strain on hospitals, as the United States was reporting over 100,000 people hospitalized for or with COVID-19 by the end of December 2020.
...

There is much more.

Biden has been hyperfocused on vaccines even though the number of breakthrough cases has increased.  He appears to have been blocking the therapeutics to red states who have effectively used them in treatments with little to no explanation about his decision.